On August 11, Zion Pharma announced the completion of its Series A+ round, raising nearly 20 million US dollars. The round was co-led by Sherpa Venture Capital and Qiming Venture Partners, with participation from Medfine Capital.
Proceeds from the financing round will mainly be used to promote the company's core programs in China and the United States to carry out clinical phase I trials, and to promote the remaining programs to complete the IND filing and screening of clinical candidates.
In addition, the funds raised will be used for the development of new projects to complete the diversification of the company's R&D pipeline and clinical internationalization.
Zion Pharma is a developer of innovative small molecule drugs intended for oncology and tumor.
The company is committed to the development of differentiated "best-in-class" and "first-in-class" drug development and focuses on the innovative drug pipeline built by breast cancer brain metastasis, enabling medical professionals to meet the clinical needs.
In just two years from the company's inception in 2018, Zion Pharma has completed the process of independent development of innovative drugs to the clinical trials.
Currently, Zion Pharma has five core pipelines, with the fastest progressing one already in Phase I clinical trial in China and the United States.